BIOLASE Inc (NASDAQ:BIOL) has been assigned an average rating of “Buy” from the six research firms that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $2.50.
BIOL has been the topic of a number of analyst reports. Dougherty & Co reissued a “buy” rating on shares of BIOLASE in a research note on Tuesday, April 30th. ValuEngine downgraded BIOLASE from a “buy” rating to a “hold” rating in a research note on Thursday, August 8th. Benchmark initiated coverage on BIOLASE in a research note on Wednesday, June 19th. They issued a “speculative buy” rating and a $2.00 price target on the stock. Ascendiant Capital Markets set a $3.00 price target on BIOLASE and gave the company a “buy” rating in a research note on Monday. Finally, Zacks Investment Research downgraded BIOLASE from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th.
In other news, major shareholder Larry N. Feinberg sold 1,000,000 shares of the firm’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $1.50, for a total value of $1,500,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.50% of the stock is owned by company insiders.
NASDAQ BIOL traded down $0.13 during trading hours on Wednesday, reaching $1.33. 14,342 shares of the company’s stock were exchanged, compared to its average volume of 40,485. The company has a market cap of $31.09 million, a PE ratio of -1.56 and a beta of 2.03. BIOLASE has a one year low of $0.91 and a one year high of $2.87. The business’s fifty day simple moving average is $1.59. The company has a debt-to-equity ratio of 1.56, a quick ratio of 1.11 and a current ratio of 1.91.
BIOLASE (NASDAQ:BIOL) last released its quarterly earnings results on Thursday, August 8th. The medical technology company reported ($0.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.03. The business had revenue of $8.65 million for the quarter, compared to analyst estimates of $12.76 million. BIOLASE had a negative return on equity of 132.62% and a negative net margin of 47.46%. On average, equities analysts forecast that BIOLASE will post -0.59 earnings per share for the current fiscal year.
BIOLASE Company Profile
BIOLASE, Inc, a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the worldwide. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; and diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening.
See Also: Compound Interest
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.